Open-Angle Glaucoma Market Insights, Epidemiology and Market Forecast-2030

Open-Angle Glaucoma Market Insights, Epidemiology and Market Forecast-2030

“DelveInsight”
DelveInsight’s Open-angle glaucoma (OAG) – Market Insights, Epidemiology, and Market Forecast—2030 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Open-Angle Glaucoma Market Insights, Epidemiology and Market Forecast-2030

 (Albany, US) DelveInsight launched a new report on Open-Angle Glaucoma Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report

  1. The total Glaucoma prevalent population was 9,819,080 in the 7MM in 2017.
  2. The total diagnosed prevalent population of Open-Angle Glaucoma (OAG) in the 7MM was 8,823,960 in 2017.
  3. The prevalent cases of OAG in the United States in 2017 was 2,749,378.
  4. The most prevalent age-group for OAG in the United States in 2017 was 70–79.

 

Key benefits of the report

1.    Open-Angle Glaucoma market report covers a descriptive overview and comprehensive insight of the Open-Angle Glaucoma epidemiology and Open-Angle Glaucoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.    Open-Angle Glaucoma market report provides insights into the current and emerging therapies.

3.    Open-Angle Glaucoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4.    Open-Angle Glaucoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Open-Angle Glaucoma market.

Request for sample pages

“Open-Angle Glaucoma Market Size was USD 3,316.71 million in the 7MM in 2017”.

 

 

The main goal of glaucoma treatment is to increase the quality of life through the reduction of intraocular pressure (IOP) to preserve visual function. In the process of IOP reduction, an ideal medication should have a schedule that is simple to follow, be least interrupting with a patient’s life, highly tolerable and affordable.

 

However, the medical treatment of Glaucoma has associated side effects, complications, and costs. There are several risk factors like age more than 60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, myopia), low educational status, smoking, African descent, and visual problems are associated with this indication and treatment pattern varies accordingly.

 

Management of the disease aims at lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogues, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors.

 

Prostaglandin analogues are the first treatment choice for many glaucoma patients. Before the entry of prostaglandins in the market, Beta-blockers were quite famous and popular for the management of Glaucoma. Ocular hypotensive agents other than beta-blockers, such as the alpha2 agonist brimonidine, maybe a more appropriate first-line therapy for ocular hypertension and glaucoma patients concurrently taking systemic beta-blockers.

 

The launch of the emerging therapies is expected to significantly impact Open-Angle Glaucoma treatment scenario in the upcoming years:-

Drugs covered

  • Bimatoprost SR
  • PDP-716
  • PRO-122
  • DE-130A
  • CKD-351
  • NCX 470
  • Bamosiran
  • ENV515
  • Nyxol
  • POLAT-001
  • Trabodenoson
  • OTX-TP

 

And many others

The key players in Open-Angle Glaucoma market are:

  • Allergan
  • Sun Pharma Advanced Research Company Limited (SPARC)
  • Laboratorios Sophia S.A de C.V.
  • Santen Pharmaceutical
  • Chong Kun Dang Pharmaceutical
  • Nicox Ophthalmics
  • Sylentis
  • Envisia Therapeutics
  • Ocuphire Pharma
  • Peregrine Ophthalmic
  • Inotek Pharmaceuticals
  • Ocular Therapeutix

 

And many others

Table of contents

1. Key Insights

 

2. Executive Summary of Open-Angle Glaucoma

 

3. Open-Angle Glaucoma Market Overview at a Glance

 

4. Open-Angle Glaucoma Disease Background and Overview

 

5. Case Reports

 

6. Open-Angle Glaucoma Epidemiology and Patient Population

 

7. United States Epidemiology

 

8. EU5 Epidemiology

 

8.1. Germany Epidemiology

 

8.2. France Epidemiology

 

8.3. Italy Epidemiology

 

8.4. Spain Epidemiology

 

8.5. United Kingdom Epidemiology

 

9. Japan Epidemiology

 

10. Open-Angle Glaucoma Treatment Algorithm, Current Treatment, and Medical Practices

 

11. Unmet Needs

 

12. Open-Angle Glaucoma Marketed Products

 

12.1. Marketed Products And Their Relative Therapeutic Classes

 

12.2. ROCKLATAN: Aerie Pharmaceuticals

 

12.3. Rhopressa: Aerie Pharmaceuticals

 

12.4. XELPROS (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited

 

12.5. EYBELIS Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl): Santen Pharmaceutical/Ube Industries

 

12.6. VYZULTA: Bausch and Lomb

 

12.7. TAPCOM/ DE-111 (Tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.

 

12.8. GLANATEC: D.Western Therapeutics Institute (DWTI)/Kowa LTD.

 

12.9. Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon Research

 

12.10. ZIOPTAN (tafluprost): Merck Sharp & Dohme Corp.

 

12.11. DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research

 

12.12. TRAVATAN Z (travoprost ophthalmic solution) 0.004%: Alcon Research, a Novartis company

 

12.13. LUMIGAN 0.01% (bimatoprost ophthalmic solution): Allergan

 

13. Open-Angle Glaucoma Emerging Therapies

 

13.1. Key Cross Competition

 

13.2. Bimatoprost SR (Sustained-Release): Allergan

13.3. PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)

 

13.4. PRO-122: Laboratorios Sophia S.A de C.V.

 

13.5. Brinzolamide Ophthalmic Suspension 1%: Perrigo Company

 

13.6. DE-130A (latanoprost): Santen Pharmaceutical

 

13.7. CKD-351: Chong Kun Dang Pharmaceutical

 

13.8. Sepetaprost (DE-126/ONO-9054): Santen Inc./Ono Pharmaceutical

 

13.9. NCX 470: Nicox Ophthalmics

 

13.10. Bamosiran (SYL040012): Sylentis

 

13.11. ENV515 (Travoprost XR): Envisia Therapeutics

 

13.12. Nyxol (Phentolamine Mesylate): Ocuphire Pharma

 

13.13. POLAT-001: Peregrine Ophthalmic

 

13.14. Failed Therapies

 

13.15. Trabodenoson: Inotek Pharmaceuticals

 

13.16. OTX-TP (Travoprost): Ocular Therapeutix

 

14. Open-Angle Glaucoma 7MM Market Analysis

 

15. United States: Market Outlook

 

15.1. United States Market Size

 

16. EU-5 countries: Market Outlook

 

16.1. Germany Market Size

 

16.2. France Market Size

 

16.3. Italy Market Size

 

16.4. Spain Market Size

 

16.5. United Kingdom Market Size

 

17. Japan Market Outlook

 

18. Access and Reimbursement Overview of Open Angle Glaucoma

 

19. Market Drivers

 

20. Market Barriers

 

21. SWOT Analysis

 

22. Appendix

 

23. DelveInsight Capabilities

 

24. Disclaimer

 

25. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

info@delveinsight.com

+919650213330

SOURCE DelveInsight

      

 

 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/